Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
33.62
+0.74 (2.25%)
At close: Jun 12, 2026, 4:00 PM EDT
33.75
+0.13 (0.39%)
After-hours: Jun 12, 2026, 7:48 PM EDT
Immunovant Market Cap
Immunovant has a market cap or net worth of $6.9 billion as of June 12, 2026. Its market cap has increased by 171.21% in one year.
Market Cap
6.90B
Enterprise Value
6.00B
1-Year Change
171.21%
Ranking
Category
Stock Price
$33.62
Market Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $6.90B, an increase of 5,449.74%. That is a compound annual growth rate of 77.77%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 12, 2026 | 6.90B | 33.97% |
| Dec 31, 2025 | 5.15B | 41.70% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Protagonist Therapeutics | 7.06B |
| Spyre Therapeutics | 7.01B |
| Praxis Precision Medicines | 6.91B |
| Vaxcyte | 6.83B |
| Kymera Therapeutics | 6.82B |
| TG Therapeutics | 6.81B |
| Legend Biotech | 6.74B |
| Apogee Therapeutics | 6.71B |